471 reports of this reaction
3.2% of all PEGVALIASE PQPZ reports
#6 most reported adverse reaction
URTICARIA is the #6 most commonly reported adverse reaction for PEGVALIASE PQPZ, manufactured by BioMarin Pharmaceutical Inc.. There are 471 FDA adverse event reports linking PEGVALIASE PQPZ to URTICARIA. This represents approximately 3.2% of all 14,737 adverse event reports for this drug.
Patients taking PEGVALIASE PQPZ who experience urticaria should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
URTICARIA is moderately reported among PEGVALIASE PQPZ users, representing a notable but not dominant share of adverse events.
In addition to urticaria, the following adverse reactions have been reported for PEGVALIASE PQPZ:
The following drugs have also been linked to urticaria in FDA adverse event reports:
URTICARIA has been reported as an adverse event in 471 FDA reports for PEGVALIASE PQPZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
URTICARIA accounts for approximately 3.2% of all adverse event reports for PEGVALIASE PQPZ, making it a notable side effect.
If you experience urticaria while taking PEGVALIASE PQPZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.